An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.
复制标题
DOI：
10.1016/j.bmcl.2016.06.019
复制
发表时间：
2016-08-01
影响因子：
2.7
通讯作者：
Lamichhane G
中科院分区：
文献类型：
--
作者：
Kaushik A;Heuer AM;Bell DT;Culhane JC;Ebner DC;Parrish N;Ippoliti JT;Lamichhane G
Innovation of new antibacterials that are effective against strains that have developed resistance to existing drugs would strengthen our ability to treat and subsequently control spread of pathogenic bacteria. Increasing incidence of infections with drug resistant bacteria has become a common occurrence in recent times. We have developed an evolved oxazolidinone, T145, which inhibits growth of Enterococcus faecalis, Staphylococcus aureus and Mycobacterium tuberculosis (Mtb) with sub μg/ml potencies that are potentially therapeutically valuable. The oxazolidinone is bactericidal against Mtb but bacteriostatic against E. faecalis and S. aureus. In addition to therapeutically valuable potency and bactericidal activity against Mtb, T145 minimizes selection of spontaneous resistant mutants, a trait that prolongs longevity of a drug in clinical use.
